Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997048443 - IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS

Publication Number WO/1997/048443
Publication Date 24.12.1997
International Application No. PCT/US1997/010650
International Filing Date 18.06.1997
Chapter 2 Demand Filed 19.12.1997
IPC
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 9/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
70Web, sheet or filament bases
A61K 31/42 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
A61K 31/4439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4545 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
CPC
A61K 31/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
42Oxazoles
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 9/0009
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
0009involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
Applicants
  • BECTON DICKINSON AND COMPANY [US]/[US] (AllExceptUS)
  • SAGE, Burton, H., Jr. [US]/[US] (UsOnly)
  • BOCK, Carl, Randolph [US]/[US] (UsOnly)
  • GREEN, Philip, G. [US]/[US] (UsOnly)
Inventors
  • SAGE, Burton, H., Jr.
  • BOCK, Carl, Randolph
  • GREEN, Philip, G.
Agents
  • HOFFMANN, Charles, R.
Priority Data
08/724,10530.09.1996US
08/724,10630.09.1996US
60/020,27719.06.1996US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS
(FR) ADMINISTRATION IONTOPHORETIQUE D'INHIBITEURS DE L'ADHESION CELLULAIRE
Abstract
(EN)
This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices (50) comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
(FR)
La présente invention a trait à de nouveaux procédés et moyens d'adminstation iontophorétique de doses thérapeutiques d'antagonistes de récepteurs d'adhésion cellulaire, cette administration se faisant de façon régulée à travers la peau. De tels composés antanogistes comprennent notamment, mais pas exclusivement, des antagonistes d'intégrines IIb/IIIa et de récepteurs de protéines adhérant à la surface des cellules apparentés. La présente invention a trait également à des moyens d'administration iontophérique (50), dont font partie les antagonistes de récepteurs d'adhésion cellulaire. Ces procédés et moyens sont utiles, seuls ou combinés à d'autres agents thérapeutiques, pour le traitement de troubles tromboemboliques ou angiogéniques, d'inflammations, de la dégradation osseuse, de métastases cancéreuses, de la rétinopathie diabétique, de la resténose, de la dégénérescence maculaire et d'autres états dus à l'adhésion cellulaire et/ou à la migration cellulaire et/ou à l'angiogenèse.
Also published as
Latest bibliographic data on file with the International Bureau